AU2017346845B2 - Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders - Google Patents

Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders Download PDF

Info

Publication number
AU2017346845B2
AU2017346845B2 AU2017346845A AU2017346845A AU2017346845B2 AU 2017346845 B2 AU2017346845 B2 AU 2017346845B2 AU 2017346845 A AU2017346845 A AU 2017346845A AU 2017346845 A AU2017346845 A AU 2017346845A AU 2017346845 B2 AU2017346845 B2 AU 2017346845B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
optionally substituted
disease
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017346845A
Other languages
English (en)
Other versions
AU2017346845A1 (en
Inventor
Fleur M. FERGUSON
Nathanael S. Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2017346845A1 publication Critical patent/AU2017346845A1/en
Application granted granted Critical
Publication of AU2017346845B2 publication Critical patent/AU2017346845B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017346845A 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders Active AU2017346845B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409457P 2016-10-18 2016-10-18
US62/409,457 2016-10-18
PCT/US2017/057126 WO2018075608A1 (en) 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders

Publications (2)

Publication Number Publication Date
AU2017346845A1 AU2017346845A1 (en) 2019-04-04
AU2017346845B2 true AU2017346845B2 (en) 2021-12-02

Family

ID=62018969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017346845A Active AU2017346845B2 (en) 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders

Country Status (6)

Country Link
US (1) US11028089B2 (enExample)
EP (1) EP3528814B1 (enExample)
JP (1) JP7086948B2 (enExample)
AU (1) AU2017346845B2 (enExample)
CA (1) CA3040173A1 (enExample)
WO (1) WO2018075608A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
AU2018392805A1 (en) 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US20220280530A1 (en) * 2019-08-08 2022-09-08 Anhui Newstar Pharmaceutical Development Co., Ltd. Prevention or treatment of diseases and disorders associated with tissue damage
US12594277B2 (en) 2020-02-14 2026-04-07 Salk Institute For Biological Studies Macrocyclic ULK1/2 inhibitors
CA3171187A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Inhibitors of ulk1/2 and methods of using same
EP4229061A4 (en) * 2020-10-14 2024-09-25 Ranok Therapeutics (Hangzhou) Co. Ltd. METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION
JP2024509864A (ja) * 2021-03-09 2024-03-05 ヤンセン ファーマシューティカ エヌ．ベー． サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリジン
CN115707469B (zh) * 2021-08-19 2024-07-02 首都医科大学附属北京朝阳医院 Dclk1抑制剂和tki在制备肺腺癌药物中的应用
CN114478539B (zh) * 2022-02-09 2024-02-02 中国人民解放军海军军医大学 一种新型dclk1抑制剂及其制备方法和应用
CN115969978A (zh) * 2022-10-27 2023-04-18 首都医科大学附属北京朝阳医院 Dclk1及il6/stat3通路抑制剂在治疗三阴性乳腺癌中的应用
CN115814094B (zh) * 2023-01-04 2024-04-02 暨南大学附属第一医院（广州华侨医院） Dclk抑制剂在制备治疗脊髓损伤的药物中的应用
CN116375713B (zh) * 2023-03-07 2024-11-19 中国人民解放军海军军医大学 一种dclk1蛋白降解靶向嵌合体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040961A1 (en) * 2009-01-06 2012-02-16 Dana-Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US20160024115A1 (en) * 2013-03-15 2016-01-28 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2017148406A1 (zh) * 2016-03-04 2017-09-08 安徽省新星药物开发有限责任公司 嘧啶类七元环化合物、其制备方法、药用组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2693152T3 (es) * 2011-05-10 2018-12-07 Kyowa Hakko Kirin Co., Ltd. Compuesto de pirimido-diazepinona
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015117083A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
RU2017104897A (ru) * 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040961A1 (en) * 2009-01-06 2012-02-16 Dana-Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US20160024115A1 (en) * 2013-03-15 2016-01-28 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2017148406A1 (zh) * 2016-03-04 2017-09-08 安徽省新星药物开发有限责任公司 嘧啶类七元环化合物、其制备方法、药用组合物及其应用

Also Published As

Publication number Publication date
CA3040173A1 (en) 2018-04-26
US20190315753A1 (en) 2019-10-17
JP2019530724A (ja) 2019-10-24
EP3528814A4 (en) 2020-07-29
EP3528814A1 (en) 2019-08-28
US11028089B2 (en) 2021-06-08
AU2017346845A1 (en) 2019-04-04
EP3528814B1 (en) 2024-08-14
JP7086948B2 (ja) 2022-06-20
WO2018075608A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3528814B1 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders
JP6553772B2 (ja) ピリミド−ジアゼピノン化合物および障害の治療方法
EP3255047B1 (en) Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
AU2017248186B2 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
CA3020172C (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
HK1259894A1 (en) Pyrimido-diazepinone compounds and methods of treating disorders
HK1247928B (en) Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
HK1247928A1 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)